Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230074 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT00230074 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 350 participants.
The verdict
NCT00230074, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
Interventions
- DRUG TCH346
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230074
The ClinicalTrials.gov registry entry for NCT00230074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TCH346 is the first listed.
NCT00230074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230074 about?
NCT00230074 is a clinical study titled "A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)". This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
What is the current status of trial NCT00230074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2004-11. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00230074?
The interventions under investigation include: TCH346 (DRUG).
Who is sponsoring clinical trial NCT00230074?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.